PHARMA MAR, S.A. «12345...» Page 4 out of 27 08/01/2025 17:51 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 01/10/2024 and 20/12/2024 Register number: 32045 06/01/2025 11:12 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The company reports the transactions performed in the context of the Share Buy-back Program between 30 December 2024 and 3 January 2025 Register number: 31999 30/12/2024 17:47 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The company reports the transactions performed in the context of the Share Buy-back Program between 23 December and 27 December 2024. Register number: 31956 19/12/2024 08:55 PHARMA MAR, S.A. On business and financial situation The Company completes recruitment for phase III LAGOON study with Zepzelca® (lurbinectedin) for the treatment of Small Cell Lung Cancer. Register number: 31838 18/12/2024 17:48 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company informs that it will carry out a program to buy-back treasury shares Register number: 31830 18/12/2024 17:41 PHARMA MAR, S.A. On corporate governance The Company reports on the approval of the Regulations of the Audit Committee and of the Appointments and Compensation and Sustainability Committee, as well as the amendment of the Board of Directors Regulations. Register number: 31829 03/12/2024 09:36 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in China. Register number: 31595 27/11/2024 08:26 PHARMA MAR, S.A. Total number of voting rights and capital Total number of voting rights and capital after capital reduction by means of the redemption of treasury shares. Register number: 31509 21/11/2024 17:39 PHARMA MAR, S.A. Other relevant information Registration within the Madrid Mercantile Registry of the resolution to reduce capital by means of the redemption of own shares. Register number: 31471 20/11/2024 12:22 PHARMA MAR, S.A. On business and financial situation The Company informs that the General Court of the European Union has declared that there is no longer any need to adjudicate and ordered the European Commission to pay Pharma Mar's costs. Register number: 31445 Page 4 out of 27 «12345...»
